ERBB2 and breast carcinoma: We designed a target trial with a protocol as similar as possible to the B-31 and N9831 randomized trials, which estimated the effect of adjuvant trastuzumab plus chemotherapy compared with chemotherapy alone in individuals with early human epidermal growth factor receptor 2-positive breast cancer.